5006802025-07-012025-09-305006802025-09-305006802025-03-315006802025-04-012025-09-305006802025-07-012025-09-30in-capmkt:OtherExpenses1Member5006802025-04-012025-09-30in-capmkt:OtherExpenses1Member5006802025-07-012025-09-30RelatedPartyTransactionDomain15006802025-06-30RelatedPartyTransactionDomain15006802025-09-30RelatedPartyTransactionDomain15006802025-07-012025-09-30RelatedPartyTransactionDomain25006802025-06-30RelatedPartyTransactionDomain25006802025-09-30RelatedPartyTransactionDomain25006802025-07-012025-09-30RelatedPartyTransactionDomain35006802025-06-30RelatedPartyTransactionDomain35006802025-09-30RelatedPartyTransactionDomain35006802025-07-012025-09-30RelatedPartyTransactionDomain45006802025-06-30RelatedPartyTransactionDomain45006802025-09-30RelatedPartyTransactionDomain45006802025-07-012025-09-30RelatedPartyTransactionDomain55006802025-06-30RelatedPartyTransactionDomain55006802025-09-30RelatedPartyTransactionDomain55006802025-07-012025-09-30RelatedPartyTransactionDomain65006802025-06-30RelatedPartyTransactionDomain65006802025-09-30RelatedPartyTransactionDomain65006802025-07-012025-09-30RelatedPartyTransactionDomain75006802025-06-30RelatedPartyTransactionDomain75006802025-09-30RelatedPartyTransactionDomain75006802025-07-012025-09-30RelatedPartyTransactionDomain85006802025-06-30RelatedPartyTransactionDomain85006802025-09-30RelatedPartyTransactionDomain85006802025-07-012025-09-30RelatedPartyTransactionDomain95006802025-06-30RelatedPartyTransactionDomain95006802025-09-30RelatedPartyTransactionDomain95006802025-07-012025-09-30RelatedPartyTransactionDomain105006802025-06-30RelatedPartyTransactionDomain105006802025-09-30RelatedPartyTransactionDomain105006802025-07-012025-09-30RelatedPartyTransactionDomain115006802025-06-30RelatedPartyTransactionDomain115006802025-09-30RelatedPartyTransactionDomain115006802025-07-012025-09-30RelatedPartyTransactionDomain125006802025-06-30RelatedPartyTransactionDomain125006802025-09-30RelatedPartyTransactionDomain125006802025-07-012025-09-30RelatedPartyTransactionDomain135006802025-06-30RelatedPartyTransactionDomain135006802025-09-30RelatedPartyTransactionDomain135006802025-07-012025-09-30RelatedPartyTransactionDomain145006802025-06-30RelatedPartyTransactionDomain145006802025-09-30RelatedPartyTransactionDomain14iso4217:INRxbrli:pureiso4217:INRxbrli:shares500680PFIZERNOTLISTEDINE182A01018Pfizer LimitedMain BoardEquity2025-04-012026-03-312025-11-122025-11-03INRCroresQuarterlySecond quarterSingle segmentPharmaceuticals2025-11-1214:00:002025-11-1215:15:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-01-31https://www.pfizerltd.co.in/files/Policy-on-Related-Party-Transactions_January-2025.pdffalsefalseNot Applicable2025-07-012025-09-30UnauditedStandalone642340000041850000068419000007000000002212700000-63320000094670000021300000142800000897900000428820000025537000000255370000065490000086000006635000000189020000000001890200000-910000018811000004575000001041.3200041.3200001. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on November 12, 2025. <BR> <BR> 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). <BR> <BR> 3. The financial results for the quarter and six months ended September 30, 2025 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in <BR> <BR> 4. During the quarter ended March 31, 2025, the Company had received requisite approvals from MIDC to assign and assume the Lease of MIDC Land and Sale of Building constructed on such land and has completed the transfer and sale of said assets. Net gain of Rs. 172.81 crore (net of carrying value of Rs. 31.75 crore and cost to sell - Premium and other charges Rs. 59.84 crore, net of recovery) is disclosed as an ‘Exceptional item’ in the financial results. <BR> <BR> 5. The shareholders in its Annual General Meeting held on July 21, 2025 approved a final dividend of Rs. 35 per equity share of Rs. 10 each (350 percent) and a special dividend of Rs.100 per equity share of Rs.10 each (1000 percent) in view of 75th year of Pfizer in India and a special dividend of Rs. 30 per equity share of Rs. 10 each (300 percent) in view of the gain on transfer of assignment of leasehold land and building constructed on such land thereon, totaling to a dividend of Rs. 165 per equity share of Rs. 10 each (1650 percent) for the financial year ended March 31, 2025. The said dividend was paid on July 25, 2025. <BR> <BR> 6. The Company has only one segment which is Pharmaceuticals. Therefore, disclosure relating to segments is not applicable and accordingly not made. <BR> <BR> 7. The Company does not have any subsidiary company or associate company or joint venture company as at September 30, 2025.2025-04-012025-09-30UnauditedStandalone1245390000010902000001354410000015869000003455500000-6506000001904900000538000002869000001757700000839510000051490000000514900000013288000001250000013413000000380770000000003807700000-1830000037894000004575000001083.2300083.230000Other Expenses897900000Other Expenses17577000001546300000750000000527490000019330000000000014480000014480000068680000033668000001128790000050047000000243970000020535000002498450000002500000029502700000025990000034767300000004605520000045750000038025400000384829000003848290000000004685000004685000006473000000001115800000250000001203000002059100000217940000096760000031720000002542000004598000002570500000064565000000075723000004605520000053800000-245500000-514600000001376000000006605000000-2644000000286900000003400000000006780000000-890400000-9190000000-7968000004352200000000-164250000005994700000000000005500000103400000000000000000204950000000000100350000000-1143900000000000000018560000075141000004830000000-7748000000-28972000000-2897200000495070000020535000001220000024500000-3100000-6200000-9100000-18300000Pfizer Limited******Pfizer Service Company BVBA, Belgium******Fellow SubsidiaryPurchase of goods or servicesOn arms length basis and in Ordinary course of business3089900000-219000000-889600000Pfizer Limited******Pfizer Products India Private Limited******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business218300000267400000386800000Pfizer Limited******Pfizer export B.V******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business231000001960000041200000Pfizer Limited******Pfizer Worldwide Services Company******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business417300000215200000190300000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business427000001330000042700000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiaryAny other transactionRent ExpenseOn arms length basis and in Ordinary course of business2000000-1000000-3000000Pfizer Limited******Pfizer East India BV******Companies holding significant incfluenceDividend paidOn arms length basis and in Ordinary course of business300070000000Pfizer Limited******Wyeth LLC******Companies holding significant incfluenceDividend paidOn arms length basis and in Ordinary course of business92690000000Pfizer Limited****** Wyeth Holdings LLC******Companies holding significant incfluenceDividend paidOn arms length basis and in Ordinary course of business26900000000Pfizer Limited****** Warner-Lambert Company LLC******Companies holding significant incfluenceDividend paidOn arms length basis and in Ordinary course of business19590000000Pfizer Limited******Parke, Davis & Company LLC******Companies holding significant incfluenceDividend paidOn arms length basis and in Ordinary course of business15770000000Pfizer Limited******John Wyeth & Brothers Ltd******Companies holding significant incfluenceDividend paidOn arms length basis and in Ordinary course of business14550000000Pfizer Limited******Pharmacia LLC******Companies holding significant incfluenceDividend paidOn arms length basis and in Ordinary course of business12940000000Pfizer Limited******John Wyeth & Brothers Ltd******Companies holding significant incfluenceAny other transactionRecovery of ExpensesOn arms length basis and in Ordinary course of business0-25000000-250000008618400000